Match!

Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience

Published on Apr 1, 2016in Molecular Cancer Research4.48
· DOI :10.1158/1535-7163.MCT-15-0795
Maria Schwaederle18
Estimated H-index: 18
(UCSD: University of California, San Diego),
Barbara A. Parker52
Estimated H-index: 52
(UCSD: University of California, San Diego)
+ 9 AuthorsRazelle Kurzrock99
Estimated H-index: 99
(UCSD: University of California, San Diego)
Abstract
By profiling their patients' tumors, oncologists now have the option to use molecular results to match patients with drug(s) based on specific biomarkers. In this observational study, 347 patients with solid advanced cancers and next-generation sequencing (NGS) results were evaluated. Outcomes for patients who received a “matched” versus “unmatched” therapy following their NGS results were compared. Eighty-seven patients (25%) were treated with a “matched” therapy, 93 (26.8%) with an “unmatched” therapy. More patients in the matched group achieved stable disease (SD) ≥ 6 months/partial response (PR)/complete response (CR), 34.5% vs. 16.1%, ( P ≤ 0.020 multivariable or propensity score methods). Matched patients had a longer median progression-free survival (PFS; 4.0 vs. 3.0 months, P = 0.039 in the Cox regression model). In analysis using PFS1 (PFS on the prior line of therapy) as a comparator to PFS after NGS, as expected, the unmatched group demonstrated a PFS2 significantly shorter than PFS1 ( P = 0.009); however, this shortening was not observed in the matched patients ( P = 0.595). Furthermore, 45.3% of the matched patients (24/53) had a PFS2/PFS1 ratio ≥1.3 compared with 19.3% of patients (11/57) in the unmatched group ( P = 0.004 univariable and P ≥ 0.057 in multivariable/propensity score analysis). Patients with a “matching-score” (the number of matched drugs divided by the number of aberrations; unmatched patients had a score of zero) > 0.2 had a median overall survival (OS) of 15.7 months compared with 10.6 months when their matching-score was ≤ 0.2, ( P = 0.040 in the Cox regression model). Matched versus unmatched patients had higher rates of SD ≥ 6 months/PR/CR and longer PFS, and improvement in OS correlated with a higher matching score in multivariable analysis. Mol Cancer Ther; 15(4); 743–52. ©2016 AACR .
  • References (41)
  • Citations (47)
References41
Newest
#1Maria Schwaederle (UCSD: University of California, San Diego)H-Index: 18
#2Melissa Zhao (UCSD: University of California, San Diego)H-Index: 2
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 8 authors...
#1Denis L. Fontes Jardim (State University of Campinas)H-Index: 12
#2Maria Schwaederle (UCSD: University of California, San Diego)H-Index: 18
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 10 authors...
#1Barbara A. Parker (UCSD: University of California, San Diego)H-Index: 52
#2Maria Schwaederle (UCSD: University of California, San Diego)H-Index: 18
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 8 authors...
#1David M. Hyman (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 35
#2Igor Puzanov (Vandy: Vanderbilt University)H-Index: 52
Last.José Baselga (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 137
view all 23 authors...
#1Vladimir Lazar (University of Paris-Sud)H-Index: 46
#2Eitan Rubin (BGU: Ben-Gurion University of the Negev)H-Index: 16
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 54 authors...
#1Maria Schwaederle (UCSD: University of California, San Diego)H-Index: 18
#2Gregory A. Daniels (UCSD: University of California, San Diego)H-Index: 24
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 8 authors...
#1Stephen Q. Wong (Peter MacCallum Cancer Centre)H-Index: 19
#2Andrew Fellowes (Peter MacCallum Cancer Centre)H-Index: 10
Last.Stephen B. Fox (Peter MacCallum Cancer Centre)H-Index: 78
view all 15 authors...
Cited By47
Newest
#1Johannes Doescher (University of Ulm)H-Index: 6
#2Stephanie E Weissinger (University of Ulm)H-Index: 6
Last.Patrick J. Schuler (University of Ulm)H-Index: 20
view all 13 authors...
#1Alex M. Li (UCSD: University of California, San Diego)
#2Amélie Boichard (UCSD: University of California, San Diego)H-Index: 4
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 3 authors...
#1Yuxian Bai (HMU: Harbin Medical University)
#2Guan WangH-Index: 1
Last.Shunchang Jiao (Chinese PLA General Hospital)
view all 10 authors...
#1Jason K. Sicklick (UCSD: University of California, San Diego)H-Index: 25
#2Shumei Kato (UCSD: University of California, San Diego)H-Index: 12
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 19 authors...
#1Jordi Rodon (University of Texas MD Anderson Cancer Center)H-Index: 23
#2Jean-Charles SoriaH-Index: 79
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 25 authors...
View next paperCancer therapy directed by comprehensive genomic profiling: a single center study